30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Pharmaceuticals

Zentalis Pharmaceuticals Inc (ZNTL)

Track

The most recent insider trading activity occurred on February 10, 2026. This involved a planned sale of 6,894 shares by Vincent Vultaggio (PAO and PFO). Prior to this, on February 9, 2026, the CEO & President Julia Marie Eastland and Chief Medical Officer Ingmar Bruns also made sales.
Stock chart
Ticker: ZNTL Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Vultaggio Vincent
PAO and PFO
1 sale — total 16,699 USD
Planned sale 10 Feb 2026
Value US$1,141,368.89 | Price 125.13 | Shares 30,346
Sale 9 Feb 2026
Value US$3,357,911.84 | Price 405.55 | Shares 50,139
Sale 9 Feb 2026
Value US$2,127.29 | Price 2.39 | Shares 889
Sale 9 Feb 2026
Value US$8,085.61 | Price 2.39 | Shares 3,379
Sale 6 Feb 2026
Value US$7,196.77 | Price 2.43 | Shares 2,962
Sale 6 Feb 2026
Value US$19,112.02 | Price 2.43 | Shares 7,866
Sale 6 Feb 2026
Value US$72,771.94 | Price 2.43 | Shares 29,951
Planned sale 3 Feb 2026
Value US$1,398.34 | Price 2.52 | Shares 556
Planned sale 3 Feb 2026
Value US$1,398.34 | Price 2.52 | Shares 556
Sale 2 Feb 2026
Value US$6,477.00 | Price 2.55 | Shares 2,540
Buy 31 Dec 2025
Value US$7,751,967.60 | Price 1.20 | Shares 6,459,973
Sale 15 Dec 2025
Value US$9,975,000.00 | Price 1.33 | Shares 7,500,000
Buy 30 Apr 2025
Value US$29,372.70 | Price 1.40 | Shares 21,000
Proposed sale 11 Feb 2025
Value US$1,374.00 | Price 2.00 | Shares 687
Buy 6 Feb 2025
Value US$45,656.00 | Price 2.28 | Shares 20,000
Sale 3 Feb 2025
Value US$4,475.57 | Price 1.71 | Shares 2,615
Sale 3 Feb 2025
Value US$24,590.83 | Price 1.71 | Shares 14,368
Sale 3 Feb 2025
Value US$22,643.14 | Price 1.71 | Shares 13,230
Proposed sale 3 Feb 2025
Value US$24,590.83 | Price 1.71 | Shares 14,368
Proposed sale 3 Feb 2025
Value US$22,643.15 | Price 1.71 | Shares 13,230
Proposed sale 3 Feb 2025
Value US$48,877.02 | Price 1.71 | Shares 28,558
Buy 31 Jan 2025
Value US$103,446.00 | Price 1.72 | Shares 60,000
Buy 31 Jan 2025
Value US$24,966.44 | Price 1.76 | Shares 14,200
Buy 31 Jan 2025
Value US$49,344.90 | Price 1.73 | Shares 28,500
Sale 2 Jan 2025
Value US$13,762.32 | Price 3.12 | Shares 4,411
Proposed sale 31 Oct 2024
Value US$28,293.60 | Price 2.86 | Shares 9,888
Planned sale 4 Oct 2024
Value US$5,097.54 | Price 3.18 | Shares 1,603
Proposed sale 31 May 2024
Value US$114,977.82 | Price 11.98 | Shares 9,597
Planned sale 31 May 2024
Value US$114,972.06 | Price 11.98 | Shares 9,597
Proposed sale 9 May 2024
Value US$42,356.41 | Price 12.62 | Shares 3,356
Sale 9 May 2024
Value US$42,352.72 | Price 12.62 | Shares 3,356
Proposed sale 12 Feb 2024
Value US$62,643.12 | Price 11.44 | Shares 5,478
Proposed sale 12 Feb 2024
Value US$29,423.29 | Price 11.44 | Shares 2,573
Proposed sale 12 Feb 2024
Value US$13,413.73 | Price 11.44 | Shares 1,173
Planned sale 12 Feb 2024
Value US$13,419.12 | Price 11.44 | Shares 1,173
Planned sale 12 Feb 2024
Value US$29,435.12 | Price 11.44 | Shares 2,573
Sale 2 Feb 2024
Value US$38,197.40 | Price 11.54 | Shares 3,310
Sale 2 Feb 2024
Value US$18,290.90 | Price 11.54 | Shares 1,585
Planned sale 2 Feb 2024
Value US$100,040.26 | Price 11.54 | Shares 8,669
Planned sale 2 Feb 2024
Value US$133,310.08 | Price 11.54 | Shares 11,552
Proposed sale 2 Feb 2024
Value US$18,287.10 | Price 11.54 | Shares 1,585
Proposed sale 2 Feb 2024
Value US$38,189.46 | Price 11.54 | Shares 3,310
Proposed sale 2 Feb 2024
Value US$23,755.92 | Price 11.54 | Shares 2,059
Proposed sale 2 Feb 2024
Value US$128,171.20 | Price 11.54 | Shares 11,109
Proposed sale 2 Feb 2024
Value US$100,019.45 | Price 11.54 | Shares 8,669
Proposed sale 2 Feb 2024
Value US$133,282.36 | Price 11.54 | Shares 11,552
Buy 13 Nov 2023
Value US$51,448.00 | Price 10.29 | Shares 5,000
Buy 10 Nov 2023
Value US$167,943.00 | Price 9.88 | Shares 17,000
Planned sale 4 Oct 2023
Value US$34,285.36 | Price 19.91 | Shares 1,722
Planned sale 4 Oct 2023
Value US$173,012.41 | Price 19.43 | Shares 8,906
Planned sale 4 Oct 2023
Value US$17,680.26 | Price 19.91 | Shares 888
Planned sale 4 Oct 2023
Value US$89,245.34 | Price 19.43 | Shares 4,594
Planned sale 4 Oct 2023
Value US$19,571.73 | Price 19.91 | Shares 983
Planned sale 4 Oct 2023
Value US$98,783.75 | Price 19.43 | Shares 5,085
Proposed sale 4 Oct 2023
Value US$207,298.08 | Price 19.50 | Shares 10,628
Proposed sale 4 Oct 2023
Value US$118,355.73 | Price 19.50 | Shares 6,068
Proposed sale 4 Oct 2023
Value US$106,925.86 | Price 19.50 | Shares 5,482
Planned sale 11 Sep 2023
Value US$125,237.50 | Price 25.05 | Shares 5,000
Proposed sale 11 Sep 2023
Value US$126,400.00 | Price 25.28 | Shares 5,000
Buy 20 Jun 2023
Value US$107,861,600.00 | Price 22.66 | Shares 4,760,000
Proposed sale 31 May 2023
Value US$490,197.96 | Price 26.46 | Shares 18,526
Proposed sale 31 May 2023
Value US$243,978.63 | Price 26.40 | Shares 9,242
Planned sale 31 May 2023
Value US$485,527.56 | Price 26.21 | Shares 18,526
Planned sale 31 May 2023
Value US$243,978.63 | Price 26.40 | Shares 9,242
Planned sale 26 May 2023
Value US$2,401,248.00 | Price 30.02 | Shares 80,000
Planned sale 14 Feb 2023
Value US$129,873.25 | Price 19.98 | Shares 6,500
Planned sale 14 Feb 2023
Value US$169,706.31 | Price 19.96 | Shares 8,501
Planned sale 14 Feb 2023
Value US$104,410.89 | Price 19.98 | Shares 5,227
Planned sale 13 Feb 2023
Value US$77,755.69 | Price 20.42 | Shares 3,807
Planned sale 13 Feb 2023
Value US$68,054.10 | Price 20.42 | Shares 3,332
Planned sale 13 Feb 2023
Value US$53,593.63 | Price 20.42 | Shares 2,624
Planned sale 6 Feb 2023
Value US$13,176.08 | Price 23.04 | Shares 572
Planned sale 6 Feb 2023
Value US$209,502.42 | Price 22.22 | Shares 9,428
Planned sale 17 Jan 2023
Value US$12,433.60 | Price 24.87 | Shares 500
Planned sale 17 Jan 2023
Value US$229,081.10 | Price 24.11 | Shares 9,500
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-10 2026-02-10 PlS Planned sale
1.6
Vultaggio Vincent

PAO and PFO

Officer
30,346 -20.0%
125.13
US$1,141,369 		30,346 -20.0% 125.13 US$1,141,369
2026-02-10 2026-02-09 S Sale
2.0
Bruns Ingmar

Chief Medical Officer

Officer
50,139 -3.9%
405.55
US$3,357,912 		50,139 -3.9% 405.55 US$3,357,912
2026-02-10 2026-02-09 S Sale
2.5
EASTLAND JULIA MARIE

CEO & President

Executive Director
6,442 +14.3%
456.10
US$4,120,698 		6,442 +14.3% 456.10 US$4,120,698
2026-02-10 2026-02-09 S Sale
1.6
Vultaggio Vincent

PAO and PFO

Officer
3,379 -2.2%
2.39
US$8,086 		3,379 -2.2% 2.39 US$8,086
2026-02-10 2026-02-06 S Sale
2.0
Bruns Ingmar

Chief Medical Officer

Officer
2,962 -8.1%
2.43
US$7,197 		2,962 -8.1% 2.43 US$7,197
2026-02-10 2026-02-06 S Sale
2.5
EASTLAND JULIA MARIE

CEO & President

Executive Director
7,866 -9.0%
2.43
US$19,112 		7,866 -9.0% 2.43 US$19,112
2026-02-10 2026-02-06 S Sale
1.6
Vultaggio Vincent

PAO and PFO

Officer
29,951 -16.0%
2.43
US$72,772 		29,951 -16.0% 2.43 US$72,772
2026-02-04 2026-02-03 PlS Planned sale
1.6
Vultaggio Vincent

PAO and PFO

Officer
556 -0.3%
2.52
US$1,398 		556 -0.3% 2.52 US$1,398
2026-02-04 2026-02-03 PlS Planned sale
1.6
Vultaggio Vincent

PAO and PFO

Officer
556 -0.3%
2.52
US$1,398 		556 -0.3% 2.52 US$1,398
2026-02-04 2026-02-02 S Sale
1.6
Vultaggio Vincent

PAO and PFO

Officer
2,540 -1.3%
2.55
US$6,477 		2,540 -1.3% 2.55 US$6,477
2026-01-08 2025-12-31 B Purchase
WALTERS GROUP
Large shareholder
6,459,973 +91.6%
1.20
US$7,751,968 		6,459,973 +91.6% 1.20 US$7,751,968
2025-12-15 2025-12-15 S Sale
1.1
Matrix Capital Management Company, LP
Large shareholder
7,500,000 -53.7%
1.33
US$9,975,000 		7,500,000 -53.7% 1.33 US$9,975,000
2025-04-30 2025-04-30 B Purchase
1.7
Myers Scott Dunseth
Non-Executive Director
21,000 +8.1%
1.40
US$29,373 		21,000 +8.1% 1.40 US$29,373
2025-02-11 2025-02-11 PrS Proposed sale
3.4
Cam Gallagher

Former Director; Former President & Interim CFO

Non-Executive Director
687
2.00
US$1,374 		687 2.00 US$1,374
2025-02-12 2025-02-06 B Purchase
2.0
Bruns Ingmar

Chief Medical Officer

Officer
20,000 +120.3%
2.28
US$45,656 		20,000 +120.3% 2.28 US$45,656
2025-02-05 2025-02-03 S Sale
1.6
Vultaggio Vincent

PAO and Interim PFO

Officer
2,615 -1.4%
1.71
US$4,476 		2,615 -1.4% 1.71 US$4,476
2025-02-05 2025-02-03 S Sale
3.3
Lackner Mark

Chief Scientific Officer

Officer
14,368 -2.7%
1.71
US$24,591 		14,368 -2.7% 1.71 US$24,591
2025-02-05 2025-02-03 S Sale
2.6
Paul Andrea

Chief Legal Officer

Officer
13,230 -1.2%
1.71
US$22,643 		13,230 -1.2% 1.71 US$22,643
2025-02-03 2025-02-03 PrS Proposed sale
3.3
Mark Lackner

Chief Scientific Officer

Officer
14,368
1.71
US$24,591 		14,368 1.71 US$24,591
2025-02-03 2025-02-03 PrS Proposed sale
2.6
Andrea Paul

Chief Legal Officer & Corporate Secretary

Officer
13,230
1.71
US$22,643 		13,230 1.71 US$22,643
2025-02-03 2025-02-03 PrS Proposed sale
3.4
Cam Gallagher

Former Director; Former President & Interim CFO

Non-Executive Director
28,558
1.71
US$48,877 		28,558 1.71 US$48,877
2025-02-04 2025-01-31 B Purchase
1.5
Skvarka Jan
Non-Executive Director
60,000 +67.0%
1.72
US$103,446 		60,000 +67.0% 1.72 US$103,446
2025-02-04 2025-01-31 B Purchase
1.5
Walker Luke Nathaniel
Non-Executive Director
14,200 +19.6%
1.76
US$24,966 		14,200 +19.6% 1.76 US$24,966
2025-02-04 2025-01-31 B Purchase
2.5
EASTLAND JULIA MARIE

CEO & President

Executive Director
28,500 +inf%
1.73
US$49,345 		28,500 +inf% 1.73 US$49,345
2025-01-03 2025-01-02 S Sale
3.3
Lackner Mark

Chief Scientific Officer

Officer
4,411 -2.3%
3.12
US$13,762 		4,411 -2.3% 3.12 US$13,762
2024-10-31 2024-10-31 PrS Proposed sale
3.7
Diana Hausman

Former Chief Medical Officer

Officer
9,888
2.86
US$28,294 		9,888 2.86 US$28,294
2024-10-04 2024-10-04 PlS Planned sale
1.6
Vultaggio Vincent

Principal Accounting Officer

Officer
1,603 -4.5%
3.18
US$5,098 		1,603 -4.5% 3.18 US$5,098
2024-05-31 2024-05-31 PrS Proposed sale
3.4
Cam Gallagher

Director; Officer - President & Interim CFO

Executive Director
9,597
11.98
US$114,978 		9,597 11.98 US$114,978
2024-05-31 2024-05-31 PlS Planned sale
3.4
Gallagher Cam

President, Interim CFO

Executive Director
9,597 -1.5%
11.98
US$114,972 		9,597 -1.5% 11.98 US$114,972
2024-05-09 2024-05-09 PrS Proposed sale
3.7
Diana Hausman

Chief Medical Officer

Officer
3,356
12.62
US$42,356 		3,356 12.62 US$42,356
2024-05-09 2024-05-09 S Sale
3.7
HAUSMAN DIANA

Chief Medical Officer

Officer
3,356 -0.9%
12.62
US$42,353 		3,356 -0.9% 12.62 US$42,353
2024-02-12 2024-02-12 PrS Proposed sale
Kevin Bunker

Former Chief Scientific Officer

Officer
5,478
11.44
US$62,643 		5,478 11.44 US$62,643
2024-02-12 2024-02-12 PrS Proposed sale
Melissa Epperly

Chief Financial Officer

Officer
2,573
11.44
US$29,423 		2,573 11.44 US$29,423
2024-02-12 2024-02-12 PrS Proposed sale
3.4
Cam Gallagher

President; Director

Non-Executive Director
1,173
11.44
US$13,414 		1,173 11.44 US$13,414
2024-02-12 2024-02-12 PlS Planned sale
3.4
Gallagher Cam

President

Executive Director
1,173 -0.2%
11.44
US$13,419 		1,173 -0.2% 11.44 US$13,419
2024-02-12 2024-02-12 PlS Planned sale
Epperly Melissa B,

Chief Financial Officer

Officer
2,573 -0.6%
11.44
US$29,435 		2,573 -0.6% 11.44 US$29,435
2024-02-05 2024-02-02 S Sale
2.6
Paul Andrea

Chief Legal Officer

Officer
3,310 -2.2%
11.54
US$38,197 		3,310 -2.2% 11.54 US$38,197
2024-02-05 2024-02-02 S Sale
3.3
Lackner Mark

Chief Scientific Officer

Officer
1,585 -0.8%
11.54
US$18,291 		1,585 -0.8% 11.54 US$18,291
2024-02-05 2024-02-02 PlS Planned sale
Epperly Melissa B,

Chief Financial Officer

Officer
8,669 -1.9%
11.54
US$100,040 		8,669 -1.9% 11.54 US$100,040
2024-02-05 2024-02-02 PlS Planned sale
3.4
Gallagher Cam

President

Executive Director
11,552 -1.8%
11.54
US$133,310 		11,552 -1.8% 11.54 US$133,310
2024-02-02 2024-02-02 PrS Proposed sale
3.3
Mark Lackner

Chief Scientific Officer

Officer
1,585
11.54
US$18,287 		1,585 11.54 US$18,287
2024-02-02 2024-02-02 PrS Proposed sale
2.6
Andrea Paul

Chief Legal Officer and Corporate Secretary

Officer
3,310
11.54
US$38,189 		3,310 11.54 US$38,189
2024-02-02 2024-02-02 PrS Proposed sale
Carrie Brownstein

Former Chief Medical Officer

Officer
2,059
11.54
US$23,756 		2,059 11.54 US$23,756
2024-02-02 2024-02-02 PrS Proposed sale
Kevin Bunker

Former Chief Scientific Officer

Officer
11,109
11.54
US$128,171 		11,109 11.54 US$128,171
2024-02-02 2024-02-02 PrS Proposed sale
Melissa Epperly

Chief Financial Officer

Officer
8,669
11.54
US$100,019 		8,669 11.54 US$100,019
2024-02-02 2024-02-02 PrS Proposed sale
3.4
Cam Gallagher

President; Director

Non-Executive Director
11,552
11.54
US$133,282 		11,552 11.54 US$133,282
2023-11-13 2023-11-13 B Purchase
3.2
Blackwell Kimberly

Chief Executive Officer

Executive Director
5,000 +2.0%
10.29
US$51,448 		5,000 +2.0% 10.29 US$51,448
2023-11-13 2023-11-10 B Purchase
3.8
Johnson David Michael
Non-Executive Director
17,000 +13.3%
9.88
US$167,943 		17,000 +13.3% 9.88 US$167,943
2023-10-06 2023-10-04 PlS Planned sale
Brownstein Carrie

Chief Medical Officer

Officer
1,722 -1.6%
19.91
US$34,285 		1,722 -1.6% 19.91 US$34,285
2023-10-06 2023-10-04 PlS Planned sale
Brownstein Carrie

Chief Medical Officer

Officer
8,906 -7.7%
19.43
US$173,012 		8,906 -7.7% 19.43 US$173,012
2023-10-06 2023-10-04 PlS Planned sale
Epperly Melissa B,

Chief Financial Officer

Officer
888 -0.2%
19.91
US$17,680 		888 -0.2% 19.91 US$17,680
2023-10-06 2023-10-04 PlS Planned sale
Epperly Melissa B,

Chief Financial Officer

Officer
4,594 -1.2%
19.43
US$89,245 		4,594 -1.2% 19.43 US$89,245
2023-10-06 2023-10-04 PlS Planned sale
Bunker Kevin D.

Chief Scientific Officer

Officer
983 -0.1%
19.91
US$19,572 		983 -0.1% 19.91 US$19,572
2023-10-06 2023-10-04 PlS Planned sale
Bunker Kevin D.

Chief Scientific Officer

Officer
5,085 -0.6%
19.43
US$98,784 		5,085 -0.6% 19.43 US$98,784
2023-10-04 2023-10-04 PrS Proposed sale
Carrie Brownstein

Chief Medical Officer

Officer
10,628
19.50
US$207,298 		10,628 19.50 US$207,298
2023-10-04 2023-10-04 PrS Proposed sale
Kevin Bunker

Chief Scientific Officer

Officer
6,068
19.50
US$118,356 		6,068 19.50 US$118,356
2023-10-04 2023-10-04 PrS Proposed sale
Melissa Epperly

Chief Financial Officer

Officer
5,482
19.50
US$106,926 		5,482 19.50 US$106,926
2023-09-13 2023-09-11 PlS Planned sale
1.5
Skvarka Jan
Non-Executive Director
5,000 -9.4%
25.05
US$125,238 		5,000 -9.4% 25.05 US$125,238
2023-09-11 2023-09-11 PrS Proposed sale
1.5
JAN SKVARKA

Director

Non-Executive Director
5,000
25.28
US$126,400 		5,000 25.28 US$126,400
2023-06-20 2023-06-20 B Purchase
1.1
Matrix Capital Management Company, LP
Large shareholder
4,760,000 +51.7%
22.66
US$107,861,600 		4,760,000 +51.7% 22.66 US$107,861,600
2023-05-31 2023-05-31 PrS Proposed sale
3.4
CAM GALLAGHER

Director; Officer

Executive Director
18,526
26.46
US$490,198 		18,526 26.46 US$490,198
2023-05-31 2023-05-31 PrS Proposed sale
3.4
Cam Gallagher

Director; Officer - President

Executive Director
9,242
26.40
US$243,979 		9,242 26.40 US$243,979
2023-05-31 2023-05-31 PlS Planned sale
3.4
Gallagher Cam

President

Executive Director
18,526 -3.8%
26.21
US$485,528 		18,526 -3.8% 26.21 US$485,528
2023-05-31 2023-05-31 PlS Planned sale
3.4
Gallagher Cam

President

Executive Director
9,242 -1.9%
26.40
US$243,979 		9,242 -1.9% 26.40 US$243,979
2023-05-31 2023-05-26 PlS Planned sale
Bunker Kevin D.

Chief Scientific Officer

Officer
80,000 -84.2%
30.02
US$2,401,248 		80,000 -84.2% 30.02 US$2,401,248
2023-02-14 2023-02-14 PlS Planned sale
Bunker Kevin D.

Chief Scientific Officer

Officer
6,500 -0.7%
19.98
US$129,873 		6,500 -0.7% 19.98 US$129,873
2023-02-14 2023-02-14 PlS Planned sale
3.4
Gallagher Cam

President

Executive Director
8,501 -1.7%
19.96
US$169,706 		8,501 -1.7% 19.96 US$169,706
2023-02-14 2023-02-14 PlS Planned sale
Epperly Melissa B,

Chief Financial Officer

Officer
5,227 -1.3%
19.98
US$104,411 		5,227 -1.3% 19.98 US$104,411
2023-02-14 2023-02-13 PlS Planned sale
Bunker Kevin D.

Chief Scientific Officer

Officer
3,807 -0.4%
20.42
US$77,756 		3,807 -0.4% 20.42 US$77,756
2023-02-14 2023-02-13 PlS Planned sale
3.4
Gallagher Cam

President

Executive Director
3,332 -0.7%
20.42
US$68,054 		3,332 -0.7% 20.42 US$68,054
2023-02-14 2023-02-13 PlS Planned sale
Epperly Melissa B,

Chief Financial Officer

Officer
2,624 -0.7%
20.42
US$53,594 		2,624 -0.7% 20.42 US$53,594
2023-02-06 2023-02-06 PlS Planned sale
3.4
Gallagher Cam

President

Executive Director
572 -0.1%
23.04
US$13,176 		572 -0.1% 23.04 US$13,176
2023-02-06 2023-02-06 PlS Planned sale
3.4
Gallagher Cam

President

Executive Director
9,428 -1.8%
22.22
US$209,502 		9,428 -1.8% 22.22 US$209,502
2023-01-18 2023-01-17 PlS Planned sale
3.4
Gallagher Cam

President

Executive Director
500 -0.1%
24.87
US$12,434 		500 -0.1% 24.87 US$12,434
2023-01-18 2023-01-17 PlS Planned sale
3.4
Gallagher Cam

President

Executive Director
9,500 -2.6%
24.11
US$229,081 		9,500 -2.6% 24.11 US$229,081
Explore more

More insider trading research around Zentalis Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America